Latest Breaking News On - Morphosys incyte - Page 1 : comparemela.com

Xencor Reports First Quarter 2024 Financial Results

Xencor Reports First Quarter 2024 Financial Results
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Mali
New-york
United-states
Japan
Xencor-alexion
Bassil-dahiyat
Las-vegas
Bart-cornelissen
Morphosys-incyte
Xencor-xmab
European-union
Seagen-inc

InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area's Early Access Program

InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area's Early Access Program
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Canada
Guangzhou
Guangdong
China
Nanjing
Jiangsu
Macao
Macau-general
Macau
Shanghai
United-states
Jilin

Relapsed DLBCL: Complete Interim Response, SCT Beats CAR T

'In patients with relapsed DLBCL in a complete remission, treatment with auto-HCT is associated with a lower rate of relapse/progression, and a longer progression-free survival [versus CAR T therapy].'

San-diego
California
United-states
New-york
University-of-rochester
American
Morphosys-incyte
Mazyar-shadman
Jonathanw-friedberg
Bristol-myers-squibb
American-society-of-hematology
International-blood-marrow-transplant-research

Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil

MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has received pricing approval for Minjuvi® (tafasitamab) from the Drugs Market Regulation Chamber (“CMED”). As a result, Knight expects to launch Minjuvi® in Brazil in the second quarter of 2024. In July 2023, ANVISA (Agência Nacional de Vigilância Sanitária) granted Market Authoriz

Canada
United-states
Montreal
Quebec
Japan
Brazil
Portuguesa
Estado-do-rio
United-kingdom
America
Brazilian
American

2023-10-16 | TSX:GUD | Press Release | Knight Therapeutics Inc

(2023-10-16 | TSX:GUD) Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil

Portuguesa
Estado-do-rio
Brazil
Montreal
Quebec
Canada
United-states
Japan
United-kingdom
Brazilian
American
America